In a study presented at Digestive Disease Week, researchers found that GLP-1 receptor agonists significantly reduced alanine aminotransferase levels in pediatric patients with metabolic dysfunction-associated steatotic liver disease (MASLD). This improvement was more pronounced in patients with type 2 diabetes compared to obesity. Despite stable BMI scores, patients showed improvement in ALT levels after treatment with GLP-1 RAs. Additional studies are needed to investigate the mechanisms by which these medications affect the liver in pediatric MASLD. This study suggests the potential for GLP-1 RAs beyond weight loss in the treatment of pediatric MASLD.
Source link
GLP-1 receptor agonists ‘have changed the playing field’ in pediatric MASLD
